News Summary: J&J predicts surge of new medicines
BIG PLANS: Johnson & Johnson says it's poised by 2017 to seek regulatory approval for a dozen new medicines and two dozen variations of existing ones. Full story
J&J expects 10-plus new drug applications by 2017
Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during a review of the health care giant's medicine business. Full story
J&J's DePuy to end 2 hip replacement systems
Johnson & Johnson's DePuy orthopedics business plans to stop selling a couple of hip replacement systems not widely used by doctors. Full story
Baby of the Week: Maliah Ayanna Davis
TODAY’s Sara Haines introduces the latest adorable additions to Johnson & Johnson’s “Baby of the Week” segment.
Johnson & Johnson CEO Shares 2013 Outlook
Alex Gorksy, Johnson & Johnson chairman & CEO, offers insight on the firm's quarter and forecast for the year ahead.
Top 3 Trades
Shares of Target are lower after the retailer warned its Q1 earnings would miss expectations, and Johnson & Johnson is up after reporting strong earnings, with the FMHR traders.
Sponsored Links
Articles
Video
Earnings Scorecard Update: JNJ, GS, & GWW
The "Squawk on the Street" news crew takes a closer look at three companies reporting first quarter numbers; including Johnson & Johnson, W.W. Grainger, and Goldman Sachs.
Johnson & Johnson Hits All-Time High
Johnson & Johnson just won approval for a new diabetes drug, and the stock is at an all-time high today. Anthony Butler, Barclays, offers insight.
Three Stocks Positioned to Deliver: Expert
David Darst, Morgan Stanley Wealth Management, explains why he is positive on Johnson & Johnson, Schlumberger, and Microsoft.
Baby boom! Check out this week’s adorable pics
Every week, with the help of Johnson & Johnson, TODAY’s Fourth Hour brings you the cutest, most adorable baby photos submitted to us by loving parents.
Johnson & Johnson to pay $8.3 million for faulty hip implant
A jury has awarded more than $8 million to a man who accused a subsidiary of Johnson & Johnson of knowingly marketing a defective hip replacement that was later recalled. NBC’s Brian Williams reports.
advertisement | ad info
Related Photos
A first aid kit made by Johnson & Johnson for sale on a store shelf in Westminster
A first aid kit made by Johnson & Johnson for sale on a store shelf in Westminster, Colorado April 14, 2009. REUTERS/Rick Wilking
File photo of products made by Johnson & Johnson for sale on a store shelf in Westminster
Products made by Johnson & Johnson for sale on a store shelf in Westminster, Colorado in this April 14, 2009, file photo. Johnson & Johnson beat Wall Street's quarterly profit estimates on sharply lower taxes, strong sales of prescription drugs and a revival of over-the-counter medicines that had be
File photo of a first aid kit made by Johnson & Johnson for sale on a store shelf in Westminster
A first aid kit made by Johnson & Johnson for sale on a store shelf in Westminster, Colorado in this April 14, 2009, file photo. Johnson & Johnson beat Wall Street's quarterly profit estimates on sharply lower taxes, strong sales of prescription drugs and a revival of over-the-counter medicines that
